Information Provided By: 
Fly News Breaks for December 21, 2015
VSAR
Dec 21, 2015 | 07:03 EDT
Citi analyst Yigal Nochomovitz says shares of Versartis are oversold after declining 50% since mid-2015. The company's long-acting growth hormone will likely be the first-to-market in pediatric growth hormone deficiency, Yigal Nochomovitz tells investors in a research note. Efficacy pf Versartis' somavaratan is "much more competitive" than the Street believes, the analyst contends. He keeps a Buy rating on the stock with a $22 price target.
News For VSAR From the Last 2 Days
There are no results for your query VSAR
